|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oettle H: Progress in the knowledge and
treatment of advanced pancreatic cancer: From benchside to bedside.
Cancer Treat Rev. 40:1039–1047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paulson AS, Tran Cao HS, Tempero MA and
Lowy AM: Therapeutic advances in pancreatic cancer.
Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nikitina EG, Urazova LN and Stegny VN:
MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.PubMed/NCBI
|
|
8
|
Piepoli A, Tavano F, Copetti M, Mazza T,
Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia
G, et al: Mirna expression profiles identify drivers in colorectal
and pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Subramani R, Gangwani L, Nandy SB,
Arumugam A, Chattopadhyay M and Lakshmanaswamy R: Emerging roles of
microRNAs in pancreatic cancer diagnosis, therapy and prognosis
(Review). Int J Oncol. 47:1203–1210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li C, Hashimi SM, Good DA, Cao S, Duan W,
Plummer PN, Mellick AS and Wei MQ: Apoptosis and microRNA
aberrations in cancer. Clin Exp Pharmacol Physiol. 39:739–746.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou
C and Zhou J: A miR-200b/200c/429-binding site polymorphism in the
3′ untranslated region of the AP-2α gene is associated with
cisplatin resistance. PLoS One. 6:e290432011. View Article : Google Scholar
|
|
12
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Funamizu N, Lacy CR, Parpart ST, Takai A,
Hiyoshi Y and Yanaga K: MicroRNA-301b promotes cell invasiveness
through targeting TP63 in pancreatic carcinoma cells. Int J Oncol.
44:725–734. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Z, Li Y, Ahmad A, Azmi AS, Kong D,
Banerjee S and Sarkar FH: Targeting miRNAs involved in cancer stem
cell and EMT regulation: An emerging concept in overcoming drug
resistance. Drug Resist Updat. 13:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang WL, Zhang JH, Wu XZ, Yan T and Lv W:
miR-15b promotes epithelial-mesenchymal transition by inhibiting
SMURF2 in pancreatic cancer. Int J Oncol. 47:1043–1053. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bai Z, Sun J, Wang X, Wang H, Pei H and
Zhang Z: MicroRNA-153 is a prognostic marker and inhibits cell
migration and invasion by targeting SNAI1 in human pancreatic
ductal adenocarcinoma. Oncol Rep. 34:595–602. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pacurari M, Addison JB, Bondalapati N, Wan
YW, Luo D, Qian Y, Castranova V, Ivanov AV and Guo NL: The
microRNA-200 family targets multiple non-small cell lung cancer
prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol.
43:548–560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Minn YK, Lee DH, Hyung WJ, Kim JE, Choi J,
Yang SH, Song H, Lim BJ and Kim SH: MicroRNA-200 family members and
ZEB2 are associated with brain metastasis in gastric
adenocarcinoma. Int J Oncol. 45:2403–2410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen A, Lin W, Chen Y, Liu L, Chen H,
Zhuang Q, Lin J, Sferra TJ and Peng J: Pien Tze Huang inhibits
metastasis of human colorectal carcinoma cells via modulation of
TGF-β1/ZEB/ miR-200 signaling network. Int J Oncol. 46:685–690.
2015. View Article : Google Scholar
|
|
20
|
Li L, Li B, Chen D, Liu L, Huang C, Lu Z,
Lun L and Wan X: miR-139 and miR-200c regulate pancreatic cancer
endothelial cell migration and angiogenesis. Oncol Rep. 34:51–58.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang L, Guo F, Huo B, Lv Y, Wang Y and
Liu W: Expression and clinical significance of the microRNA-200
family in gastric cancer. Oncol Lett. 9:2317–2324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M,
Zhang W, Chen W, Pan C, Liu Q, et al: MiR-200b and miR-15b regulate
chemotherapy-induced epithelial-mesenchymal transition in human
tongue cancer cells by targeting BMI1. Oncogene. 31:432–445. 2012.
View Article : Google Scholar
|
|
25
|
Funamizu N, Hu C, Lacy C, Schetter A,
Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, et al:
Macrophage migration inhibitory factor induces epithelial to
mesenchymal transition, enhances tumor aggressiveness and predicts
clinical outcome in resected pancreatic ductal adenocarcinoma. Int
J Cancer. 132:785–794. 2013. View Article : Google Scholar
|
|
26
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent
and acquired gemcitabine resistance in human pancreatic
adenocarcinoma cells. Clin Cancer Res. 10:2307–2318. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Funamizu N, Kamata Y, Misawa T, Uwagawa T,
Lacy CR, Yanaga K and Manome Y: Hydroxyurea decreases gemcitabine
resistance in pancreatic carcinoma cells with highly expressed
ribonucleotide reductase. Pancreas. 41:107–113. 2012. View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
30
|
Funamizu N, Okamoto A, Kamata Y, Misawa T,
Uwagawa T, Gocho T, Yanaga K and Manome Y: Is the resistance of
gemcitabine for pancreatic cancer settled only by overexpression of
deoxycytidine kinase? Oncol Rep. 23:471–475. 2010.PubMed/NCBI
|
|
31
|
Funamizu N, Lacy CR, Fujita K, Furukawa K,
Misawa T, Yanaga K and Manome Y: Tetrahydrouridine inhibits cell
proliferation through cell cycle regulation regardless of cytidine
deaminase expression levels. PLoS One. 7:e374242012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kamada M, Akiyoshi K, Akiyama N, Funamizu
N, Watanabe M, Fujioka K, Ikeda K and Manome Y: Cholangiocarcinoma
cell line TK may be useful for the pharmacokinetic study of the
chemotherapeutic agent gemcitabine. Oncol Rep. 32:829–834. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Funamizu N, Lacy CR, Kamada M, Yanaga K
and Manome Y: MicroRNA-203 induces apoptosis by upregulating Puma
expression in colon and lung cancer cells. Int J Oncol.
47:1981–1988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Chen Y, Lin Y, Wang X, Cui X,
Zhang Z, Xian G and Qin C: Novel crosstalk between KLF4 and ZEB1
regulates gemcitabine resistance in pancreatic ductal
adenocarcinoma. Int J Oncol. 51:1239–1248. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gillen S, Schuster T, Meyer Zum
Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant
therapy in pancreatic cancer: A systematic review and meta-analysis
of response and resection percentages. PLoS Med. 7:e10002672010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abou-Alfa GK, Letourneau R, Harker G,
Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager
RL, Eckhardt SG, et al: Randomized phase III study of exatecan and
gemcitabine compared with gemcitabine alone in untreated advanced
pancreatic cancer. J Clin Oncol. 24:4441–4447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Louvet C, Labianca R, Hammel P, Lledo G,
Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, et
al GERCOR; GISCAD: Gemcitabine in combination with oxaliplatin
compared with gemcitabine alone in locally advanced or metastatic
pancreatic cancer: Results of a GERCOR and GISCAD phase III trial.
J Clin Oncol. 23:3509–3516. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vickers MM, Powell ED, Asmis TR, Jonker
DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W and Moore MJ:
Comorbidity, age and overall survival in patients with advanced
pancreatic cancer - results from NCIC CTG PA.3: A phase III trial
of gemcitabine plus erlotinib or placebo. Eur J Cancer.
48:1434–1442. 2012. View Article : Google Scholar
|
|
40
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nagano H, Tomimaru Y, Eguchi H, Hama N,
Wada H, Kawamoto K, Kobayashi S, Mori M and Doki Y: MicroRNA-29a
induces resistance to gemcitabine through the Wnt/β-catenin
signaling pathway in pancreatic cancer cells. Int J Oncol.
43:1066–1072. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin Y, Ge X, Wen Y, Shi ZM, Chen QD, Wang
M, Liu LZ, Jiang BH and Lu Y: MiRNA-145 increases therapeutic
sensibility to gemcitabine treatment of pancreatic adenocarcinoma
cells. Oncotarget. 7:70857–70868. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gui Z, Luo F, Yang Y, Shen C, Li S and Xu
J: Oridonin inhibition and miR 200b 3p/ZEB1 axis in human
pancreatic cancer. Int J Oncol. 50:111–120. 2017. View Article : Google Scholar
|
|
44
|
Pan B, Feng B, Chen Y, Huang G, Wang R,
Chen L and Song H: MiR-200b regulates autophagy associated with
chemoresistance in human lung adenocarcinoma. Oncotarget.
6:32805–32820. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Asakura T, Yamaguchi N, Ohkawa K and
Yoshida K: Proteasome inhibitor-resistant cells cause EMT-induction
via suppression of E-cadherin by miR-200 and ZEB1. Int J Oncol.
46:2251–2260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
47
|
Yang S, He P, Wang J, Schetter A, Tang W,
Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, et al: A
novel MIF signaling pathway drives the malignant character of
pancreatic cancer by targeting NR3C2. Cancer Res. 76:3838–3850.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu Z and Li Y, Takwi A, Li B, Zhang J,
Conklin DJ, Young KH, Martin R and Li Y: miR-301a as an NF-κB
activator in pancreatic cancer cells. EMBO J. 30:57–67. 2011.
View Article : Google Scholar
|
